Skip to main content

Table 6 Immune-related adverse events

From: Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study

Events, n (%)

All (n = 49)

Pneumonia

4 (8.2%)

Telangiectasia

4 (8.2%)

Hypothyroidism

1 (2.0%)

Hyperuricemia

2 (4.1%)

Myocarditis

2 (4.1%)

Enteritis

1 (2.0%)

Impaired pituitary function

1 (2.0%)

Hypokalemia

1 (2.0%)

Hyperglycemia

1 (2.0%)

Thyroiditis

1 (2.0%)

Rash/itching

1 (2.0%)